 The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry APR: Registry to detect any major teratogenic effect when administered to pregnant women: abacavir ZIAGEN, ABC, abacavirlamivudine combination EPZICOM, EPZ, abacavirlamivudinezidovudine combination TRIZIVIR, TZV, abacavirdolutegravirlamivudine combination TRIUMEQ, TRI, adefovir dipivoxil HEPSERA, ADV, amprenavir AGENERASE, APV, atazanavir REYATAZ, ATV, atazanavircobicistat combination EVOTAZ, EVO, cobicistat TYBOST, COBI, darunavir PREZISTA, DRV, darunavircobicistat combination PREZCOBIXTM, REZOLSTATM, PCX, delavirdine mesylate RESCRIPTOR, DLV, didanosine VIDEX, VIDEX EC, ddI, dolutegravir TIVICAY, DTG, emtricitabine tenofovir alafenamide DESCOVY,DVY efavirenz SUSTIVA, STOCRIN, EFV, efavirenzemtricitabine tenofovir disoproxil combination ATRIPLA ATR, elvitegravir VITEKTA, EVG, elvitegravircobicistatemtricitabinetenofovir alafenamide combination GENVOYA, GEN, elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate combination STRIBILD, STB, emtricitabine EMTRIVA, FTC, enfuvirtide FUZEON, T-20, entecavir BARACLUDE, ETV, etravirine INTELENCE, ETR, fosamprenavir calcium LEXIVA, FOS, indinavir CRIXIVAN, IDV, lamivudine EPIVIR, 3TC, lamivudineraltegravir combination DUTREBISTM, DUT, lamivudinezidovudine combination COMBIVIR, ZDV3TC, lopinavirritonavir combination KALETRA, ALUVIA, LPVr, maraviroc SELZENTRY, CELSENTRI, MVC, nelfinavir VIRACEPT, NFV, nevirapine VIRAMUNE, VIRAMUNE XRTM, NVP, raltegravir ISENTRESS, RAL, rilpivirine EDURANT, RPV, rilpivirineemtricitabinetenofovir alafenamide GENVOYA,GEN rilpivirineemtricitabinetenofovir disoproxil combination COMPLERA, CPA; EVIPLERA, EPA, ritonavir NORVIR, RTV, saquinavir FORTOVASE, SQV-SGC, saquinavir mesylate INVIRASE, SQV-HGC, stavudine ZERIT, d4T, telbivudine SEBIVO, TYZEKA, LdT, tenofovir alafenamide VEMLIDY, TAF, tenofovir disoproxil fumarate VIREAD, TDF, tenofovir disoproxil fumarate emtricitabine TRUVADA, TVD, tipranavir APTIVUS, TPV, zalcitabine HIVID, ddC, and zidovudine RETROVIR, ZDV. Zidovudine is indicated for use in the second and third trimesters of pregnancy to reduce the risk of maternal-fetal HIV transmission. There are also several other completed and ongoing studies in maternal-fetal transmission with other therapies. However, the safety of prenatal zidovudine or any other antiretroviral therapy exposure to the fetus has not been established. 